196 related articles for article (PubMed ID: 23800680)
1. Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications.
Jiang Y; Janku F; Subbiah V; Angelo LS; Naing A; Anderson PM; Herzog CE; Fu S; Benjamin RS; Kurzrock R
Oncotarget; 2013 Jun; 4(6):884-9. PubMed ID: 23800680
[TBL] [Abstract][Full Text] [Related]
2. PTPRD copy number variants and Ewing's sarcoma: Strengthening the association and therapeutic implications.
Saskin A; Seath K; Tihy F; Lemyre E; Davis J; Halal F; Armstrong L
Cancer Genet; 2019 Jun; 235-236():28-30. PubMed ID: 31072725
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.
Anderson PM; Bielack SS; Gorlick RG; Skubitz K; Daw NC; Herzog CE; Monge OR; Lassaletta A; Boldrini E; Pápai Z; Rubino J; Pathiraja K; Hille DA; Ayers M; Yao SL; Nebozhyn M; Lu B; Mauro D
Pediatr Blood Cancer; 2016 Oct; 63(10):1761-70. PubMed ID: 27362300
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
5. Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
Peyser ND; Du Y; Li H; Lui V; Xiao X; Chan TA; Grandis JR
PLoS One; 2015; 10(8):e0135750. PubMed ID: 26267899
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study.
Pappo AS; Vassal G; Crowley JJ; Bolejack V; Hogendoorn PC; Chugh R; Ladanyi M; Grippo JF; Dall G; Staddon AP; Chawla SP; Maki RG; Araujo DM; Geoerger B; Ganjoo K; Marina N; Blay JY; Schuetze SM; Chow WA; Helman LJ
Cancer; 2014 Aug; 120(16):2448-56. PubMed ID: 24797726
[TBL] [Abstract][Full Text] [Related]
7. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Veeriah S; Brennan C; Meng S; Singh B; Fagin JA; Solit DB; Paty PB; Rohle D; Vivanco I; Chmielecki J; Pao W; Ladanyi M; Gerald WL; Liau L; Cloughesy TC; Mischel PS; Sander C; Taylor B; Schultz N; Major J; Heguy A; Fang F; Mellinghoff IK; Chan TA
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9435-40. PubMed ID: 19478061
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.
Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I; Leitch I; Badola S; Chang S; Zhu M; Tolcher A
J Clin Oncol; 2012 May; 30(15):1849-56. PubMed ID: 22508822
[TBL] [Abstract][Full Text] [Related]
9. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.
Di Conza G; Buttarelli M; Monti O; Pellegrino M; Mancini F; Pontecorvi A; Scotlandi K; Moretti F
Mol Cancer Ther; 2012 Jun; 11(6):1247-56. PubMed ID: 22461661
[TBL] [Abstract][Full Text] [Related]
10. Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor.
Hyun O J; Luber BS; Leal JP; Wang H; Bolejack V; Schuetze SM; Schwartz LH; Helman LJ; Reinke D; Baker LH; Wahl RL
J Nucl Med; 2016 May; 57(5):735-40. PubMed ID: 26795289
[TBL] [Abstract][Full Text] [Related]
11. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
12. Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors.
Jiang Y; Subbiah V; Janku F; Ludwig JA; Naing A; Benjamin RS; Brown RE; Anderson P; Kurzrock R
PLoS One; 2014; 9(8):e93676. PubMed ID: 25119929
[TBL] [Abstract][Full Text] [Related]
13. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
[TBL] [Abstract][Full Text] [Related]
14. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Vishwamitra D; Wang Y; Maywald RL; Buford AS; Fokt I; Skora S; Wang J; Naing A; Lazar AJ; Rohren EM; Daw NC; Subbiah V; Benjamin RS; Ratan R; Priebe W; Mikos AG; Amin HM; Ludwig JA
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27576731
[TBL] [Abstract][Full Text] [Related]
15. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.
Pappo AS; Patel SR; Crowley J; Reinke DK; Kuenkele KP; Chawla SP; Toner GC; Maki RG; Meyers PA; Chugh R; Ganjoo KN; Schuetze SM; Juergens H; Leahy MG; Geoerger B; Benjamin RS; Helman LJ; Baker LH
J Clin Oncol; 2011 Dec; 29(34):4541-7. PubMed ID: 22025149
[TBL] [Abstract][Full Text] [Related]
16. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
[TBL] [Abstract][Full Text] [Related]
17. Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis.
Ortiz B; Fabius AW; Wu WH; Pedraza A; Brennan CW; Schultz N; Pitter KL; Bromberg JF; Huse JT; Holland EC; Chan TA
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8149-54. PubMed ID: 24843164
[TBL] [Abstract][Full Text] [Related]
18. Loss of Tyrosine Phosphatase Delta Promotes Gastric Cancer Progression via Signal Transducer and Activator of Transcription 3 Pathways.
Wu L; Gao L; Kong D; Xue H
Dig Dis Sci; 2019 Nov; 64(11):3164-3172. PubMed ID: 31041642
[TBL] [Abstract][Full Text] [Related]
19. IL-6 induces tumor suppressor protein tyrosine phosphatase receptor type D by inhibiting miR-34a to prevent IL-6 signaling overactivation.
Zhang F; Wang B; Qin T; Wang L; Zhang Q; Lu Y; Song B; Yu X; Li L
Mol Cell Biochem; 2020 Oct; 473(1-2):1-13. PubMed ID: 32602014
[TBL] [Abstract][Full Text] [Related]
20. Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning?
Ho AL; Schwartz GK
J Clin Oncol; 2011 Dec; 29(34):4581-3. PubMed ID: 22025158
[No Abstract] [Full Text] [Related]
[Next] [New Search]
